Cargando…
m(6)A RNA methyltransferases METTL3/14 regulate immune responses to anti‐PD‐1 therapy
An impressive clinical success has been observed in treating a variety of cancers using immunotherapy with programmed cell death‐1 (PD‐1) checkpoint blockade. However, limited response in most patients treated with anti‐PD‐1 antibodies remains a challenge, requiring better understanding of molecular...
Autores principales: | Wang, Lingling, Hui, Hui, Agrawal, Kriti, Kang, Yuqi, Li, Na, Tang, Rachel, Yuan, Jiajun, Rana, Tariq M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7560214/ https://www.ncbi.nlm.nih.gov/pubmed/32964498 http://dx.doi.org/10.15252/embj.2020104514 |
Ejemplares similares
-
Roles of the m6A methyltransferases METTL3, METTL14, and WTAP in pulmonary tuberculosis
por: Zhang, Tian-Ping, et al.
Publicado: (2022) -
ALKBH5 regulates anti–PD-1 therapy response by modulating lactate and suppressive immune cell accumulation in tumor microenvironment
por: Li, Na, et al.
Publicado: (2020) -
Solution structure of the RNA recognition domain of METTL3-METTL14 N(6)-methyladenosine methyltransferase
por: Huang, Jinbo, et al.
Publicado: (2018) -
Levels and clinical significance of the m6A methyltransferase METTL14 in patients with coronary heart disease
por: Guo, Fengxia, et al.
Publicado: (2023) -
MiR‐103‐3p targets the m(6)A methyltransferase METTL14 to inhibit osteoblastic bone formation
por: Sun, Zhongyang, et al.
Publicado: (2021)